GENFIT S.A Operating Income 2019-2021 | GNFT
GENFIT S.A operating income from 2019 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
GENFIT S.A Annual Operating Income
(Millions of US $) |
| 2021 |
$38 |
| 2020 |
$-95 |
| 2019 |
$-65 |
| 2018 |
$-82 |
GENFIT S.A Quarterly Operating Income
(Millions of US $) |
| 2021-12-31 |
|
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.172B |
$0.101B |
|
Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France.
|
